Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction
without previous therapy will be treated with one of two chemotherapy combinations before and
after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin
and Docetaxel (FLOT), the others Oxaliplatin and Capecitabin (XELOX). Main objective of the
study is histopathological regression rate.